Compare Pfizer Inc (PFE) vs Raymond James Financial, Inc. (RJF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs Raymond James Financial, Inc. — how do they compare? Pfizer Inc trades at $27.88 (market cap $158.39B), while Raymond James Financial, Inc. trades at $175.81 (market cap $33.96B). The key difference: Pfizer Inc is far larger — about 4.7× Raymond James Financial, Inc.'s market cap, and Pfizer Inc pays the higher dividend (6.19%). Which is the better fit depends on your goals.
| PFE | RJF | |
|---|---|---|
Market Cap | $158.39B | $33.96B |
Volume | 29,869,932 | — |
Sector | Health | Financials |
52-Week High | $29.02 | $181.18 |
52-Week Low | $23.60 | $140.89 |
Enterprise Value | $209.89B | — |
Dividend Yield | 6.19% | 1.22% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $27.78, down 2.36% today, with a consensus price target of $28.33 suggesting modest upside. The stock shows mixed technical signals with bullish moving averages but neutral oscillators. Recent earnings have consistently beaten expectations, though revenue declined from pandemic peaks. The company maintains strong cash flow generation and a solid dividend yield of approximately 3.1%.
Pfizer presents a value opportunity with reasonable valuation metrics and dividend stability, but faces headwinds from post-COVID revenue normalization and patent expirations. The company's pipeline progress in obesity and oncology could drive future growth, though execution risks remain. Analyst sentiment leans cautious with 59% hold ratings.
Raymond James Financial (RJF) trades at $176.55, down 0.98% on the day, with a bullish earnings trend after beating estimates for three consecutive quarters. The stock shows mixed technical signals with bearish overall momentum but bullish moving averages. Recent Q3 2026 results showed record revenues of $3.93 billion, up 16% year-over-year, driven by wealth management growth and investment banking recovery.
RJF presents a compelling investment case with strong fundamentals and analyst support, though technical indicators suggest near-term caution. The consensus price target of $184.11 implies 4.3% upside potential, with no sell ratings among 25 analysts. Key risks include rising expenses and capital markets volatility, while the company's advisor recruitment momentum and dividend payments provide stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About Raymond James Financial, Inc.
Raymond James Financial is a financial holding company whose major operations include wealth management, investment banking, asset management, and commercial banking. The company has more than 14,000 employees and supports more than 5,000 independent contractor financial advisors across the United States, Canada, and the United Kingdom. Approximately 90% of the company's revenue is from the U.S. and 70% is from the company's wealth-management segment.
Read more on RJF →
